SCD4 Inhibitors

Common SCD4 Inhibitors include, but are not limited to CAY 10566 CAS 944808-88-2, CDDO Methyl Ester CAS 218600-53-4, Myriocin (ISP-1) CAS 35891-70-4, Betulinic Acid CAS 472-15-1 and Ursodeoxycholic acid CAS 128-13-2.

SCD4 inhibitors are a category of compounds designed to interact with and modulate the activity of the stearoyl-CoA desaturase 4 (SCD4) enzyme. SCD4 is a key player in cellular lipid metabolism, participating in the conversion of saturated fatty acids to monounsaturated fatty acids. These inhibitors are meticulously tailored to engage specific binding sites within the active domain of the SCD4 enzyme, influencing its catalytic function. Through their interaction with SCD4, these inhibitors hold the ability to impact the biosynthesis of monounsaturated fatty acids, which play pivotal roles in various cellular processes.

By targeting SCD4, these inhibitors offer a unique means to gain insights into the intricate mechanisms of lipid metabolism and its broader implications for cellular homeostasis. Through their modulation of fatty acid profiles, SCD4 inhibitors may affect various cellular pathways and processes, including lipid storage, membrane fluidity, and signaling. Investigation into the effects of SCD4 inhibitors contributes to the understanding of cellular responses to alterations in fatty acid composition. Overall, these inhibitors provide a valuable tool for unraveling the intricate interplay between lipid metabolism and cellular functions, enhancing our comprehension of fundamental biological processes.